- Conditions
- Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy, Tay Sachs Disease, Sandhoffs Disease, Wolman Disease, I-Cell Disease, Sanfilippo Syndrome, GM1 Gangliosidosis
- Interventions
- Clofarabine, Total body Irradiation, Melphalan, Hematopoietic Stem Cell Transplantation, Alemtuzumab, mycophenylate mofetil, Cyclosporine A, Hydroxyurea
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1321–1344
of 17,842
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Anaemia
- Interventions
- GSK1278863 75 mg, GSK1278863 500 mg, Moxifloxacin 400 mg, Placebo matching GSK1278863, Placebo matching Moxifloxacin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Pancreatic Cancer
- Interventions
- FOLFIRINOX, Losartan, Nivolumab, SBRT, Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more
- Conditions
- Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy, Non-obstructive Hypertrophic Cardiomyopathy
- Interventions
- mavacamten
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 31
- States / cities
- Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 26 more
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Tafasitamab, Lenalidomide
- Drug
- Lead sponsor
- MorphoSys AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 10
- States / cities
- Bakersfield, California • Los Angeles, California • Redondo Beach, California + 7 more
- Conditions
- Colitis, Ulcerative
- Interventions
- placebo, MultiStem low dose, MultiStem high dose
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 37
- States / cities
- San Francisco, California • Lafayette, Colorado • Lakewood, Colorado + 24 more
- Conditions
- Myelogenous Leukemia, Acute
- Interventions
- RO5503781 MBP, RO5503781 SDP, Idarubicin, Daunorubicin, Cytarabine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Valhalla, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- Human Immunodeficiency Virus Type 1
- Interventions
- D/C/F/TAF, Boosted Protease Inhibitor (bPI), FTC/TDF
- Drug
- Lead sponsor
- Janssen R&D Ireland
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 35 more
- Conditions
- Breast Cancer
- Interventions
- Cryoablation, Ipilimumab, Nivolumab
- Procedure · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pain, Postoperative
- Interventions
- Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant), ON-Q PainBuster Post-op Pain relief System
- Drug
- Lead sponsor
- Innocoll
- Industry
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Boynton Beach, Florida
- Conditions
- Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Interventions
- TAK-007, Chemotherapy Agents
- Biological · Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2038
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more
- Conditions
- Heart Failure
- Interventions
- BiDil XR, BiDil Immediate Release (IR)
- Drug
- Lead sponsor
- Arbor Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Anniston, Alabama • Coral Gables, Florida • Jacksonville, Florida + 2 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Zanubrutinib, Bendamustine, Rituximab, Venetoclax
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 18
- States / cities
- Augusta, Georgia • Chicago, Illinois • Boston, Massachusetts + 13 more
- Conditions
- Multiple Myeloma
- Interventions
- TAA-specific CTLs, TAA-specific CTLs- fixed dose
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 3
- States / cities
- Houston, Texas
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Siplizumab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 8 Years to 45 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Iowa City, Iowa • New York, New York + 2 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- UMEC/VI, TIO/OLO, Albuterol/salbutamol
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 9
- States / cities
- Clearwater, Florida • Orlando, Florida • St Louis, Missouri + 6 more
- Conditions
- Melanoma
- Interventions
- CMP-001, Pembrolizumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Duarte, California + 9 more
- Conditions
- Healthy Volunteers
- Interventions
- TAK-954, TAK-954 Placebo
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Diffuse Large B Cell Lymphoma, Post Transplant Lymphoproliferative Disorder, Primary Mediastinal (Thymic) Large B-cell Lymphoma
- Interventions
- DA-EPOCH-R for DLBCL, PTLD, AND PMBCL, Methotrexate, Etoposide, Doxorubicin, Vincristine, Rituximab, Cyclophosphamide, Prednisone, G-CSF
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Minimal Residual Disease, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute
- Interventions
- Clofarabine, Cytarabine intravenous, Methotrexate, Intrathecal (IT) Cytarabine
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Charlotte, North Carolina • Seattle, Washington
- Conditions
- X-linked Hypohidrotic Ectodermal Dysplasia
- Interventions
- EDI200
- Drug
- Lead sponsor
- Edimer Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- San Francisco, California • Cincinnati, Ohio
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- rAAVrh74.MCK.GALGT2, PLACEBO (Saline)
- Biological · Other
- Lead sponsor
- Kevin Flanigan
- Other
- Eligibility
- 9 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Lymphoma
- Interventions
- Carfilzomib, Lenalidomide, Rituximab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Enteritis
- Interventions
- SGX201 (delayed release beclomethasone 17,21-dipropionate)
- Drug
- Lead sponsor
- Soligenix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Boston, Massachusetts